CCR5 antagonists: a new tool in fighting HIV.
Chemokine receptors are essential for cell entry by HIV. The two chemokine receptors most relevant to this process are CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) since a delayed onset of disease can be achieved by inhibition of either receptor. Therefore, chemokine receptor antagonists, in particular inhibitors of CCR5, represent a promising new class of anti-HIV agents. In this review, we summarise current drug candidates, give an insight into how they interact with CCR5, and discuss requirements and restrictions for these compounds.
Jülg
Boris
B
Department of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University, Munich, Germany.
Goebel
Frank-Detlef
FD
D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology; D065100:CCR5 Receptor Antagonists; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D019713:Receptors, CCR5 / Q000502:physiology / Q000627:therapeutic use*; D019718:Receptors, CXCR4 / Q000502:physiology; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D019713:Receptors, CCR5; D019718:Receptors, CXCR4